81 FR 81149 - Government-Owned Invention; Availability for Licensing

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 81, Issue 222 (November 17, 2016)

The invention listed below is owned by an agency of the U.S. Government and is available for licensing in the U.S. to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

[Federal Register Volume 81, Number 222 (Thursday, November 17, 2016)]
[Notices]
[Page 81149]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-27676]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Invention; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing in the U.S. to achieve 
expeditious commercialization of results of federally-funded research 
and development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by communicating with the indicated licensing contact at the Technology 
Transfer and Intellectual Property Office, National Institute of 
Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 
20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement 
will be required to receive copies of unpublished scientific data.

SUPPLEMENTARY INFORMATION: Technology description follows.

Polyvalent Influenza Virus-Like Particles (VLPs) and Use as Vaccines

    Description of Technology: This virus-like particle (VLP) vaccine 
technology for influenza viruses, based on a mixture of VLPs expressing 
the hemagglutinin protein or the neuraminidase protein from influenza 
virus strains belonging to different virus subtypes, has demonstrated 
broad protection against lethal challenge in mice with various 
influenza virus strains and virus subtypes. Results from ferret and 
mouse studies demonstrate broad heterosubtypic protection against 
various influenza virus subtypes further supporting and strengthening 
the proposed application of this technology as a universal influenza 
virus vaccine.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications:
     Vaccines
    Competitive Advantages:
     Broad/universal protection against influenza viruses
     does not require reformulating vaccine each year as is 
currently necessary with vaccines available on the market
     can potentially provide protection against novel influenza 
viruses that may arise in the future, including potentially pandemic 
influenza viruses
    Inventors: Dr. Jeffery Taubenberger of NIAID.
    Publications: Schwartzman, et al. An Intranasal Virus-Like Particle 
Vaccine Broadly Protects Mice from Multiple Subtypes of Influenza A 
Virus. 2015. MBio. 6(4): e01044-15.
    Intellectual Property: HHS Reference No. E-195-2014, U.S. 
Provisional Application No. 62/014,814; PCT/US2015/029843.
    Licensing Contact: Dr. Jenish Patel, (240) 669-2894, 
[email protected].
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize this invention, especially for GMP 
manufacture and clinical evaluation. For collaboration opportunities, 
please contact Dr. Jenish Patel, (240) 669-2894, [email protected].

    Dated: November 14, 2016.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2016-27676 Filed 11-16-16; 8:45 am]
 BILLING CODE 4140-01-P